Treatment with a GLP −1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders

Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP −1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar diso rder (BD) were recruited.

Source: European Neuropsychopharmacology - September 1, 2017 Category: Psychiatry & Psychology Authors: Rodrigo B. Mansur, Andre Zugman, Juhie Ahmed, Danielle S. Cha, Mehala Subramaniapillai, Yena Lee, Julie Lovshin, Jung G. Lee, Jae-Hon Lee, Vladislav Drobinin, Jason Newport, Elisa Brietzke, Eva Z. Reininghaus, Kang Sim, Maj Vinberg, Natalie Rasgon, Tomas Source Type: research